COX-1 inhibition vs COX-2 selective inhibition
How to tell COX-1 inhibition and COX-2 selective inhibition apart when a board question makes them look alike.
COX-1 is stomach/platelet protection; COX-2 is inflammation-focused with thrombotic tradeoff when selectively blocked.
Side by side
Nonselective NSAID or aspirin pattern with gastric mucosal injury, renal prostaglandin effects, and platelet thromboxane changes.
Celecoxib-like pattern with less platelet/GI COX-1 effect but concern for thrombotic cardiovascular risk.
COX-1 normally supports gastric protection and platelet thromboxane production.
COX-2 is induced in inflammation and supports prostacyclin balance in vascular endothelium.
GI bleeding or platelet inhibition points toward COX-1 involvement; aspirin is irreversible on platelets.
Selective COX-2 inhibitor language points toward less GI toxicity but higher thrombotic concern in susceptible patients.
The trap
Both reduce inflammation, both can injure kidneys, and most nonselective NSAIDs (ibuprofen, naproxen, indomethacin, ketorolac) block both isoforms. The discriminating axis is the COX-1/COX-2 tradeoff: COX-1 makes thromboxane A2 in platelets and protective prostaglandins in gastric mucosa, so blocking it causes GI bleeding and antiplatelet effect; COX-2 makes prostacyclin in endothelium, so selectively blocking it (celecoxib) preserves gastric COX-1 (less GI bleed) but tips the platelet-endothelium balance toward thrombosis (increased MI and stroke risk). Aspirin is the only NSAID that irreversibly acetylates platelet COX-1, which is why it stays effective at 81 mg daily for cardiovascular prevention.
The repair move
For NSAID questions, decide whether the clue is platelet/GI COX-1 or inflammation-selective COX-2.
Try a free question
CoreA patient takes a nonselective NSAID and develops gastric irritation plus reversible platelet dysfunction. Which enzyme blockade best explains these effects?
Show answer and explanation
Answer: A. COX-1 inhibition. COX-1 supports gastric mucosal protection and platelet thromboxane production, so inhibition causes GI and platelet effects.
Why the other choices are tempting
- B. Selective COX-2 inhibition is designed to reduce GI toxicity but can increase thrombotic risk.
- C. P2Y12 blockade is clopidogrel/ticagrelor antiplatelet physiology.
- D. HMG-CoA reductase inhibition is statin physiology.
- E. SGLT2 blockade causes renal glucose wasting.
Flashcards
Tap a card to flip it.
What is the fastest separator for COX-1 inhibition vs COX-2 selective inhibition?
COX-1 is stomach/platelet protection; COX-2 is inflammation-focused with thrombotic tradeoff when selectively blocked.
What clue should make you choose COX-1 inhibition?
Nonselective NSAID or aspirin pattern with gastric mucosal injury, renal prostaglandin effects, and platelet thromboxane changes.
Quick answers
What is the fastest way to tell COX-1 inhibition from COX-2 selective inhibition?
COX-1 is stomach/platelet protection; COX-2 is inflammation-focused with thrombotic tradeoff when selectively blocked.
What is the key clue for COX-1 inhibition?
Nonselective NSAID or aspirin pattern with gastric mucosal injury, renal prostaglandin effects, and platelet thromboxane changes.
What is the key clue for COX-2 selective inhibition?
Celecoxib-like pattern with less platelet/GI COX-1 effect but concern for thrombotic cardiovascular risk.
What is the common trap with COX-1 inhibition vs COX-2 selective inhibition?
Both reduce inflammation, both can injure kidneys, and most nonselective NSAIDs (ibuprofen, naproxen, indomethacin, ketorolac) block both isoforms. The discriminating axis is the COX-1/COX-2 tradeoff: COX-1 makes thromboxane A2 in platelets and protective prostaglandins in gastric mucosa, so blocking it causes GI bleeding and antiplatelet effect; COX-2 makes prostacyclin in endothelium, so selectively blocking it (celecoxib) preserves gastric COX-1 (less GI bleed) but tips the platelet-endothelium balance toward thrombosis (increased MI and stroke risk). Aspirin is the only NSAID that irreversibly acetylates platelet COX-1, which is why it stays effective at 81 mg daily for cardiovascular prevention.